LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

74.78 -1.14

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

74.44

Max

75.94

Galvenie mērījumi
By Trading Economics
Ienākumi	-100M -229M
Pārdošana	46M 203M
Peļņas marža	-112.808
Darbinieki	1,402
EBITDA	4.7B 4.6B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.7% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.3B 12B
Iepriekšējā atvēršanas cena	75.92
Iepriekšējā slēgšanas cena	74.78

Ziņu noskaņojums

By Acuity

50%

147 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. marts 19:18 UTC

Galvenie tirgus virzītāji

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Nikkei May Decline on Energy Costs Concerns -- Market Talk

2026. g. 11. marts 23:51 UTC

Tirgus saruna

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

2026. g. 11. marts 23:41 UTC

Tirgus saruna

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

2026. g. 11. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

2026. g. 11. marts 22:29 UTC

Tirgus saruna

Australia Shares Set to Fall in Early Trade -- Market Talk

2026. g. 11. marts 21:47 UTC

Peļņas

Liontown Resources: Market Tailwinds Strengthening Outlook

2026. g. 11. marts 21:46 UTC

Peļņas

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources Says FY26 Guidance Unchanged

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources 1H Unit Operating Costs A$985/Ton

2026. g. 11. marts 21:44 UTC

Peļņas

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Revenue A$207.5 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Net Loss A$184 Million

2026. g. 11. marts 21:12 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss $7.5M >VGZ

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss/Shr 6c >VGZ

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 11. marts 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Papa John's Draws Fresh Takeover Interest -- 2nd Update

2026. g. 11. marts 20:26 UTC

Peļņas

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

2026. g. 11. marts 20:19 UTC

Galvenie ziņu notikumi

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

2026. g. 11. marts 20:15 UTC

Peļņas

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

2026. g. 11. marts 20:12 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

2026. g. 11. marts 19:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

2026. g. 11. marts 19:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

2026. g. 11. marts 18:59 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

2026. g. 11. marts 18:43 UTC

Galvenie ziņu notikumi

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

26.7% augšup

Prognoze 12 mēnešiem

Vidējais 95.86 USD 26.7%

Augstākais 110 USD

Zemākais 72 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

147 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.